Ann: Trading Halt, page-12

Issuer
Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) (“EXL”, “Elixinol Global” or the “Company”
Transaction
Placement of approximately 21.6 million new fully paid ordinary shares (“New Shares” to raise approximately A$40.0 million (the “Placement”
Lead Manager
Bell Potter Securities Limited (“Bell Potter” or the “Lead Manager”
Last Close Price
A$2.15
Offer Price
A$1.85 (14.0% discount to last close, 6.7% discount to the 5 day VWAP)
Shares on Issue
102,875,981
Market Cap. (at Last Close)
A$221,183,359 (at last close)
Book Close1
9.00am (Sydney Time) Friday, 28 September 2018
Note: (1) The Company and Lead Manager reserve the right to close the book early and without notice
Company Description
Company Overview
Elixinol Global through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products. Elixinol Global’s businesses include:
 Elixinol USA: which was founded in 2014, is a manufacturer and global distributor of industrial hemp based dietary supplement and skincare products, with operations based out of Colorado, USA;
 Hemp Foods Australia: which was founded in 1999, is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products;
 Elixinol Australia: which was founded in 2014 to participate in the emerging Australian medicinal cannabis market and submitted licence applications for cultivation and manufacture to the Office of Drug Control in early 2018. These applications are currently pending approval.
Investment Highlights


Offer Structure
Transaction
Placement of New Shares at A$1.85 per share. The Placement is approximately 21.0% of the issued capital and will be conducted under the 15% placement capacity of the Company in accordance with ASX L.R 7.1 and additional 10% placement capacity of the Company in accordance with ASX LR.7.1A.
New Shares under the Placement will rank pari passu with existing ordinary shares.
Use of Proceeds
Use of proceeds USA
Includes increased sales & marketing, stage 3 production facility and potential acquisition opportunities
Europe
Sales and marketing expansion
General working capital Total
Amount (A$) A$25.6m
A$2.0m
A$12.4m
A$40.0m

Pricing
Offer Price
Last close
5 day VWAP 10 day VWAP
Price per share
A$1.85
Offer Price discount to Last Close and VWAP
A$2.15
A$1.983 6.7% A$1.975 6.3%
14.0%
Capital Structure
Capital Structure

Shares

Existing shares on issue
102,875,981
Placement shares issued

21,621,622
Shares on issue post Offer
124,497,603